SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes,
Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
This is a clinical trial of tamoxifen and an aromatase inhibitor that will be administered by mouth, which is standard of care and docetaxel, cyclophosphamide, paclitaxel, doxorubicin, and/or 5-FU selected regimens that will be administered by IV, and is
IRB Protocol #
KYRA ANDERSON at -- or KYRA.ANDERSON@UCDENVER.EDU
Dept Of Veterans Affairs Medical Center University of Colorado Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 10 years. A follow up period will consist of clinic visits for up to 15 years. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.Eligibility criteria include but are not limited to 18 years or older with breast cancer.